Michel De Wilde has a long career in Vaccine Research and Development. He currently consults for the Vaccine Communiuty.
From 2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at sanofi pasteur.
While at sanofi pasteur, Michel drove the development and licensure by the FDA and other Regulatory bodies of a number of products. Sanofi Dengue vaccine was developed under his supervision.
Michel was also instrumental in driving the acquisition of and defining the integration model for two biotech companies: Acambis and VaxDesign.
Prior to joining sanofi pasteur, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility to become Vice President, Research & Development. De Wilde has played a key role as a research scientist in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine candidate.
Michel D e Wilde received is Ph.D. in Biochemistry in 1976, from the Free University of Brussels